Trial site
Renovatio Clinical
The Woodlands, Texas 77380, United StatesNot linked to an institution yet
- 18running trials
- 7closed trials
The trials here
What the 25 trials at this site are about, from their registry records.
- Phase
- Phase 312 trials
- Phase 1/24 trials
- Phase 24 trials
- Phase 13 trials
- Phase 41 trial
- Status
- Recruiting11 trials
- Active, not recruiting6 trials
- Completed4 trials
- Terminated2 trials
- Enrolling by invitation1 trial
- Withdrawn1 trial
- Lead sponsor
- Hoffmann-La Roche4 trials
- Janssen Research & Development, LLC2 trials
- Takeda2 trials
- United Therapeutics2 trials
- Amgen1 trial
- and 14 more
Running trials
Recruiting
A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer
NCT07906717· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC
NCT07725796· Phase 1· UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.· Source
Contact: Pablo Villarreal
Recruiting
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
NCT07284602· Phase 3· PureTech· Source
Contact: Ather Siddiqi, MD
Recruiting
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
NCT07422480· Phase 3· Takeda· Source
Contact: Mahran Shoukier (principal investigator)
Recruiting
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06769698· Phase 2· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215· Phase 3· Hoffmann-La Roche· Source
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401· Phase 3· Pfizer· Source
Active, not recruiting
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06624085· Phase 1· Hoffmann-La Roche· Source
Recruiting
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
NCT06562543· Phase 4· Takeda· Source
Contact: Jonathon Lu (principal investigator)
Active, not recruiting
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774· Phase 3· Amgen· Source
Recruiting
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
NCT06084936· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239· Phase 3· Hoffmann-La Roche· Source
Enrolling by invitation
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
NCT04905693· Phase 3· United Therapeutics· Source
Active, not recruiting
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
NCT04919811· Phase 2· Nuvation Bio Inc.· Source
Active, not recruiting
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
NCT04674683· Phase 3· HUYABIO International, LLC.· Source
Active, not recruiting
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT03485209· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
NCT03045029· United Therapeutics· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error